<DOC>
	<DOCNO>NCT01160861</DOCNO>
	<brief_summary>This Phase Ib , randomize , blind , placebo-controlled , multiple-ascending dose study patient seasonal perennial allergic rhinitis investigate safety , tolerability , pharmacokinetics ( PK ) MEMP1972A .</brief_summary>
	<brief_title>A Study Investigate Safety , Tolerability , Pharmacokinetics MEMP1972A Patients With Allergic Rhinitis</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<criteria>Diagnosis allergic rhinitis In good health , determine clinically significant finding medical history , 12lead ECG , vital sign Males females surgically sterilize , post menopausal past year , use two acceptable method contraception pregnancy least 6 month dose study drug History clinical manifestation significant metabolic , hepatic , renal , hematologic , immunodeficiency , pulmonary , cardiovascular , gastrointestinal , urologic , neurologic , psychiatric disorder History anaphylaxis , hypersensitivity drug allergy Use nonbiologic investigational drug participation investigational study nonbiologic drug within 30 day prior dose Use biologic investigational therapy participation investigational study involve biologic therapy within 3 month prior dose Positive blood test chronic viral infection : hepatitis B surface antigen , hepatitis C virus antibody , HIV antibody</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>